Korean stock · KOSPI 207940

Samsung Biologics Stock (207940.KS): Price, Tickers, US Listings and Research

Samsung Biologics is a contract development and manufacturing organisation (CDMO) that makes antibody and other biologic drugs for drugmakers, with 785,000 litres of capacity in Songdo, Incheon, plus a 60,000-litre plant in Rockville, Maryland, bought from GSK (Human Genome Sciences) in March 2026; in July 2026 it agreed to buy Swiss peptide CDMO PolyPeptide Group through a CHF 44.31-per-share tender offer (about KRW 2.7tn), funded by a rights issue. On 2025-11-01 it split off its biosimilar business, Samsung Bioepis, into a new holding company, Samsung Epis Holdings, which has traded separately on KOSPI (code 0126Z0) since 2025-11-24. Revenue from continuing operations in 2025 was KRW 4.56tn, 95.6% from products (contract manufacturing) and 4.4% from services; in 1H 2026, 59.3% of revenue came from Europe, 23.1% from the Americas, 16.7% from Korea and 0.9% from elsewhere.

Samsung Biologics building in Songdo, Incheon, with the company name on its glass facade. — Photo: Narubaru7, CC BY 4.0, via Wikimedia Commons

Samsung Biologics (207940), Oct 23, 2026

삼성바이오로직스 · Biopharmaceutical contract manufacturing (CDMO) · KRW 1,326 per USD for dollar figures.

Share priceKRW 1,466,000about $1,105.59

Market valueKRW 67.9tnabout $51bn

12-month change-17.9%in won, price only

Foreign ownership12.7%of listed shares

Tickers and where it trades

The main line is the common share on the Korea Exchange under the six-digit code 207940. How Korean stock codes work.

Venue	Ticker	Data symbol / ratio	Notes
Korea Exchange	207940 KOSPI	Yahoo Finance: 207940.KS	Common shares

None found: EDGAR full-text search returns no F-6 (ADR) registration for Samsung Biologics and EDGAR has no company record under that name; the London Stock Exchange instrument search returns nothing; the Luxembourg Stock Exchange search shows only a Deutsche Bank structured note referencing the shares, not a GDR; the 1H26 report lists only the KOSPI listing (since 2016-11-10). No OTC symbol was found in web searches, and the OTC Markets site could not be queried (checked 2026-10-18). Samsung Epis Holdings (KRX 0126Z0), the holding company for Samsung Bioepis that was split off on 2025-11-01, is a separate KOSPI-listed company, not another line of 207940.

Samsung Biologics share price, last 12 months

Main businesses

Contract manufacturing (CMO) of antibodies and other biologics: 95.6% of 2025 revenue (products)
Services and other: 4.4% of 2025 revenue (the company also offers contract development, CDO: cell lines and process development)
New modalities: ADC plant (running since March 2025), mRNA, Samsung Organoids research services
Pending: PolyPeptide Group (peptide CDMO) tender offer; settlement now expected by 2026-12-31

Earnings dates

Latest results date on file: 3Q26 on Oct 21, 2026.

Next results: no date announced yet. Korean listed companies must file quarterly and half-year reports within 45 days of the period end (annual reports within 90 days), and many announce the results date on DART in advance (company IR page).

Owning it from abroad

Samsung Biologics has no ADR, GDR or confirmed OTC line, so direct exposure is via KRX shares (207940) through a broker with Korea market access, or indirectly via Korea-focused ETFs such as EWY (check current holdings); the split-off biosimilar business trades separately on KRX as Samsung Epis Holdings (0126Z0).

See buying Korean stocks by broker and Korean stocks you can buy in the US.

Largest shareholders

Samsung C&T Corporation: 43.06% (as of 2026-10-06)
Samsung Electronics Co., Ltd.: 31.22% (as of 2026-10-06)
National Pension Service: 6.88% (as of 2026-07-29)
Largest shareholder (Samsung C&T) and related parties combined: 74.29% (as of 2026-10-06)

Dividends

Samsung Biologics paid no dividend for FY2023, FY2024 or FY2025 and reports no dividend in the last five years. Its stated capital-allocation policy puts investment first (Bio Campus 2 and 3 in Songdo, overseas investment and M&A), and it says it will re-announce a dividend policy in three years (1H26 report).

Research on Samsung Biologics

Stock Splits and Bonus Issues in Korea: 772 Events Show the Pop Fades Within 60 Trading Days (-11.79% After Ex-Rights)Oct 14, 2026

About this page

Numbers. Price, market value and foreign ownership from the Korea Exchange (KRX) as of Oct 23, 2026; 12-month price history from Yahoo Finance. The page is refreshed when new research is published on this site.
Facts (listings, earnings dates, shareholders, businesses) were checked on 2026-10-18 against these sources:

All Korean stock pages →Foreign investor flows →KOSPI valuation →Start here →

Information only. It is not investment advice.